Publications by authors named "Ina Zhang"
Article Synopsis
- In the absence of direct comparisons, researchers used unanchored matching-adjusted indirect comparisons to evaluate the effectiveness of zanubrutinib against ibrutinib and rituximab in patients with relapsed or refractory marginal zone lymphoma (MZL).
- They applied logistic propensity score models to align patient data from two phase II trials with aggregate data from larger studies involving ibrutinib and rituximab, focusing on factors like previous treatments, MZL subtype, and patient age.
- Results indicated that zanubrutinib provided significant improvements in overall response and progression-free survival compared to both ibrutinib and rituximab for patients with previously treated MZL.
Introduction: Anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) is a complement-mediated autoimmune disease in which unpredictable and relapsing attacks on the central nervous system cause irreversible and accumulating damage. Comparative efficacy of new NMOSD therapies, such as ravulizumab, with established therapies is critical in making informed treatment decisions.
Methods: Efficacy of ravulizumab relative to established AQP4-Ab+ NMOSD treatments, such as eculizumab, inebilizumab, and satralizumab, was evaluated in a Bayesian network meta-analysis (NMA).
Article Synopsis
- * An indirect comparison study was conducted to evaluate the effectiveness of brexu-cel against pirtobrutinib, using patient data to account for various prognostic factors, including disease stage and prior treatments.
- * Results indicated that brexu-cel led to significantly higher response rates and improved progression-free survival compared to pirtobrutinib, suggesting it might be a more effective treatment option for this patient population.
Thymic carcinoma (TC) is a rare cancer and patients failing initial chemotherapy (relapse/refractory) face limited therapeutic options given no approved options or consensus standard of care. This study aimed to identify and summarize clinical outcomes of all regimens evaluated in clinical trials of relapsed or refractory patients. Interventional trials enrolling advanced TC patients who failed first-line chemotherapy and reported outcomes in this group were eligible for inclusion in our systemic literature review (SLR).
View Article and Find Full Text PDFPurpose: The purpose of this study was to evaluate clinical outcomes of standard therapies in previously treated, advanced colorectal cancer (CRC) patients.
Methods: A systematic literature review was conducted in Embase, MEDLINE, and CENTRAL databases (January 2000-July 2021), annual oncology conferences (2019-2021), and clinicaltrials.gov to identify studies evaluating the use of licensed interventions in second-line or later settings.
Introduction: Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease defined by attacks on the central nervous system that cause irreversible damage. Recent approval of NMOSD therapies warrants investigations of comparative efficacy to inform treatment decisions.
Methods: A network meta-analysis (NMA) of all U.
Aim: A systematic review and network meta-analysis were conducted to evaluate the efficacy of pembrolizumab + pemetrexed + platinum relative to other regimens in metastatic nonsquamous non-small-cell lung cancer (NSq-NSCLC).
Patients & Methods: Eligible studies evaluated first-line regimens in NSq-NSCLC patients without known targetable mutations. Relative treatment effects were synthesized with random effects proportional hazards Bayesian network meta-analyses.